Healthcare Analytics MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ComponentBy Delivery ModeBy ApplicationBy End-use

Healthcare analytics refers to software platforms and related implementation and support services that collect, process and interpret clinical, financial and operational data generated across hospitals, physician networks, health insurers and life science organizations. These platforms range from descriptive reporting and dashboarding tools to predictive models that flag clinical or financial risk and prescriptive tools that recommend a specific next action. Buyers include hospital and health system IT and quality departments, health insurers managing population risk, and life science companies using real-world data for research and post-market surveillance.

The global healthcare analytics market is valued at USD 58 billion in 2025 and is set to reach USD 260.19 billion by 2034, a compound annual growth rate of 18.04% across the 2026-2034 forecast period. The study tracks the market across USD 25.8 billion in 2020, USD 49.8 billion in 2024, USD 69.02 billion in 2026 and USD 134 billion in 2030.

40% of 2025 revenue sits in Descriptive Analysis, worth USD 23.2 billion and rising to USD 72.85 billion at 28% by 2034, the largest type line in both years. Growth is fastest in Prescriptive Analysis at 22.95% and slowest in Descriptive Analysis at 13.37%. Share moves toward Predictive Analysis and Prescriptive Analysis and away from Descriptive Analysis, though no line shrinks in revenue terms.

Cut by component, the largest line is Software: 55% of 2025 revenue, worth USD 31.9 billion, and 58% at USD 150.91 billion by 2034. Services grows faster at 19.01% against 18.85%, moving from 30% of revenue to 32% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.

Geographically, 42% of 2025 revenue sits in North America (USD 24.36 billion rising to USD 98.87 billion) ahead of Europe at 24% and USD 13.92 billion. Middle East and Africa is smallest, at 5%. Share shifts toward Asia Pacific over the forecast period, which is what makes the regional split worth reading rather than assuming.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 18.04% takes the market from USD 58 billion in 2025 to USD 260.19 billion in 2034, against 17.59% recorded over the 2020-2025 historical period.
• The largest line by type is Descriptive Analysis, worth USD 23.2 billion and 40% of revenue in 2025, rising to USD 72.85 billion and 28% by 2034.
• Prescriptive Analysis is the fastest-growing line at 22.95%, lifting its share from 22% in 2025 to 32% in 2034 and its revenue from USD 12.76 billion to USD 83.26 billion.
• Against a base case of USD 260.19 billion in 2034, the study also reports a bear case at USD 228.97 billion and a bull case at USD 291.41 billion, with the assumptions behind each set out separately.
• North America holds 42% of global revenue in 2025 at USD 24.36 billion, the largest of the five regions tracked, and reaches USD 98.87 billion by 2034.
• Within North America, the United States is the worked country example, at USD 20.71 billion in 2025; 85.02% of regional revenue in the base year, and USD 83.05 billion by 2034.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global healthcare analytics market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 18.04% rate carrying the total.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Prescriptive Analysis grows faster than Descriptive Analysis. Prescriptive Analysis grows at 22.95% across 2026-2034 against 13.37% for Descriptive Analysis, the widest spread on the type axis. Shares follow: 22% to 32% for Prescriptive Analysis, 40% to 28% for Descriptive Analysis. In absolute terms Prescriptive Analysis rises from USD 12.76 billion to USD 83.26 billion, while Descriptive Analysis rises from USD 23.2 billion to USD 72.85 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

The regional balance moves. Asia Pacific moves from 23% of revenue in 2025 to 29% in 2034, worth USD 13.34 billion rising to USD 75.46 billion. Against that, North America at 42% moving to 38%, Europe at 24% moving to 22%, Latin America at 6% moving to 6%, Middle East and Africa at 5% moving to 5%, a fall in share, not in revenue. Revenue added in this market is therefore concentrating geographically rather than spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

The series never breaks trajectory. The market moves through USD 25.8 billion in 2020, USD 49.8 billion in 2024, USD 58 billion in 2025, USD 69.02 billion in 2026, USD 134 billion in 2030 and USD 260.19 billion in 2034. No year breaks the trajectory, and the 18.04% forecast rate compares with 17.59% recorded over 2020-2025, a continuation rather than an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

The fastest line decides the blended rate

Separate the 18.04% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 228.97 billion rather than USD 260.19 billion by 2034

Upside case: USD 291.41 billion by 2034

Concentration on the type axis

In North America, 42% of global revenue puts 2025 at USD 24.36 billion rising to USD 98.87 billion in 2034. Among the five regions it ranks first by revenue in both years.

By 2034 the share stands at 38%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The type mix reported at global level applies here, with Descriptive Analysis the largest line at 40% of 2025 revenue and Prescriptive Analysis the fastest-growing at 22.95%. North America is reported axis by axis and country by country in the full study.

The largest single market in North America is the United States, at USD 20.71 billion in 2025 and USD 83.05 billion in 2034. Because it is 85.02% of the region in the base year, North America's totals move with this one country rather than with a spread of them. Regional revenue of USD 24.36 billion in 2025 and USD 98.87 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

the United States buys along the same lines as the market globally; Descriptive Analysis first at 40% of 2025 revenue and 28% in 2034, Prescriptive Analysis fastest at 22.95% on a share moving from 22% to 32%. Since 85.02% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The United States carries its own type breakdown in the full report.

In the United States, healthcare analytics platforms sit at the intersection of data-privacy law and medical-device law. Where a product only aggregates, reports, or benchmarks health information without informing a specific clinical decision, its principal obligation is compliance with the Health Insurance Portability and Accountability Act's privacy and security rules, enforced by the Department of Health and Human Services' Office for Civil Rights, alongside the expectation that underlying health IT modules hold ONC certification for interoperability. Where an analytics tool instead generates or supports a specific diagnostic or treatment recommendation, it can cross into Software as a Medical Device territory, bringing it under the Food and Drug Administration's classification and premarket review framework and associated quality-system and labelling obligations.

Competition in the United States runs between the suppliers this study tracks: McKesson Corporation, Optum, Inc., IBM, Oracle, SAS Institute, Inc., IQVIA, Verisk Analytics, Inc., Elsevier, Medeanalytics, Inc., Truven Health Analytics, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Health Catalyst and Innovaccer Inc.. The commercially relevant division is 40% of 2025 revenue in Descriptive Analysis, where the volume is, against 22.95% growth in Prescriptive Analysis, where share moves. Per-company positioning and share at country level are in the full report only.

Within North America, Canada accounts for 14.98% of regional revenue and 6.29% of the global total, worth USD 3.65 billion in 2025 and USD 15.82 billion by 2034.

In Europe, 24% of global revenue puts 2025 at USD 13.92 billion rising to USD 57.24 billion in 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

22% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Segment composition follows the global pattern: Descriptive Analysis largest at 40% of 2025 revenue, Prescriptive Analysis fastest at 22.95%. Europe is reported axis by axis and country by country in the full study.

Germany is the largest market within Europe, generating USD 4.18 billion in 2025 and projected to reach USD 17.17 billion by 2034. Its 30.03% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. The region itself runs USD 13.92 billion to USD 57.24 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Descriptive Analysis at 40% of 2025 revenue, easing to 28% by 2034, and the fastest is Prescriptive Analysis at 22.95%, from 22% to 32%. With 30.03% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for Germany appears on its own in the full report.

In Germany, healthcare analytics products are governed first by data-protection law: the General Data Protection Regulation, applied nationally through the Federal Data Protection Act and supervised by the state data-protection authorities, sets requirements for the lawful processing of health information, including heightened safeguards for special-category data. Where an analytics tool qualifies as software intended for a medical purpose, it additionally falls under the EU Medical Device Regulation, requiring risk classification, a conformity assessment often involving a notified body, and CE marking before it can be placed on the market. Tools seeking reimbursement as digital health applications face further review by the Federal Institute for Drugs and Medical Devices.

McKesson Corporation, Optum, Inc., IBM, Oracle, SAS Institute, Inc., IQVIA, Verisk Analytics, Inc., Elsevier, Medeanalytics, Inc., Truven Health Analytics, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Health Catalyst and Innovaccer Inc. are the suppliers covered in Germany. Volume sits in Descriptive Analysis at 40% of 2025 revenue; movement sits in Prescriptive Analysis at 22.95% growth.

Within Europe, the United Kingdom accounts for 27.01% of regional revenue and 6.48% of the global total, worth USD 3.76 billion in 2025 and USD 15.45 billion by 2034.

4.79% of global revenue is generated in France; USD 2.78 billion in 2025, reaching USD 11.45 billion in 2034, and 19.97% of Europe.

USD 13.34 billion of 2025 revenue is generated in Asia Pacific, 23% of the global healthcare analytics market rising to USD 75.46 billion in 2034. Among the five regions it ranks third by revenue in both years.

Its share rises to 29% over the forecast period, so the region grows faster than the market's 18.04% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The type mix reported at global level applies here, with Descriptive Analysis the largest line at 40% of 2025 revenue and Prescriptive Analysis the fastest-growing at 22.95%. Asia Pacific is reported axis by axis and country by country in the full study.

35.01% of Asia Pacific's base-year revenue comes from China; USD 4.67 billion, rising to USD 28.67 billion by 2034. 35.01% of the region in the base year makes it the largest market here without making it the region. Set against USD 13.34 billion and USD 75.46 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in China follows the type mix reported at global level: Descriptive Analysis is the largest line at 40% of 2025 revenue, moving to 28% by 2034, while Prescriptive Analysis grows fastest at 22.95% and takes its share from 22% to 32%. Since 35.01% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for China appears on its own in the full report.

In China, an analytics product that qualifies as software intended for diagnosis, monitoring, or treatment support is regulated by the National Medical Products Administration, which assigns it a risk-based classification and requires registration or filing before marketing, along with conformity to applicable national standards for medical device software. Analytics offerings that instead process personal health information without a clinical-decision function fall under the country's data-security and personal-information-protection framework, which requires a lawful basis for processing, security assessment, and controls on cross-border transfer of health data. Suppliers operating in both categories must satisfy device registration and data-governance obligations together rather than treating either as sufficient alone.

The suppliers tracked in this study (McKesson Corporation, Optum, Inc., IBM, Oracle, SAS Institute, Inc., IQVIA, Verisk Analytics, Inc., Elsevier, Medeanalytics, Inc., Truven Health Analytics, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Health Catalyst and Innovaccer Inc.) compete in China across the type lines above. The commercially relevant division is 40% of 2025 revenue in Descriptive Analysis, where the volume is, against 22.95% growth in Prescriptive Analysis, where share moves.

5.76% of global revenue is generated in Japan; USD 3.34 billion in 2025, reaching USD 16.6 billion in 2034, and 25.04% of Asia Pacific.

India is sized at USD 2.67 billion in 2025, rising to USD 18.11 billion by 2034; 4.6% of global revenue and 20.02% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Latin America holds 6% of the global healthcare analytics market in 2025, worth USD 3.48 billion rising to USD 15.61 billion in 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

By 2034 the share stands at 6%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

The type mix reported at global level applies here, with Descriptive Analysis the largest line at 40% of 2025 revenue and Prescriptive Analysis the fastest-growing at 22.95%. The full report breaks Latin America out along every axis and by country.

USD 1.91 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 8.59 billion by 2034. Its 54.89% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 3.48 billion and USD 15.61 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Brazil buys along the same lines as the market globally; Descriptive Analysis first at 40% of 2025 revenue and 28% in 2034, Prescriptive Analysis fastest at 22.95% on a share moving from 22% to 32%. Because the country carries 54.89% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Per-type revenue for Brazil appears on its own in the full report.

In Brazil, software that functions as a medical device, including analytics tools that generate clinical recommendations, is regulated by the National Health Surveillance Agency, which assigns a risk classification and requires registration before the product can be marketed, together with conformity to applicable quality and labelling requirements. Analytics products that process personal health data, regardless of device status, are additionally subject to the General Data Protection Law, which sets requirements for lawful processing, consent, and security of sensitive health information and is enforced by the National Data Protection Authority. A supplier operating in this market must satisfy both the device-registration route and the data-protection regime at the same time.

The suppliers tracked in this study (McKesson Corporation, Optum, Inc., IBM, Oracle, SAS Institute, Inc., IQVIA, Verisk Analytics, Inc., Elsevier, Medeanalytics, Inc., Truven Health Analytics, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Health Catalyst and Innovaccer Inc.) compete in Brazil across the type lines above. Two different problems sit on the same axis: holding Descriptive Analysis at 40% of 2025 revenue, and taking Prescriptive Analysis while it grows at 22.95%.

Within Latin America, Mexico accounts for 29.89% of regional revenue and 1.79% of the global total, worth USD 1.04 billion in 2025 and USD 4.68 billion by 2034.

Middle East and Africa holds 5% of the global healthcare analytics market in 2025, worth USD 2.9 billion rising to USD 13.01 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

5% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Descriptive Analysis leads here as it does globally, at 40% of 2025 revenue, and Prescriptive Analysis again grows fastest at 22.95%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.87 billion in 2025 and USD 3.9 billion in 2034. At 30% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 2.9 billion in 2025 and USD 13.01 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Descriptive Analysis at 40% of 2025 revenue, easing to 28% by 2034, and the fastest is Prescriptive Analysis at 22.95%, from 22% to 32%. Because the country carries 30% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by type for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, medical device software, including analytics tools intended to support diagnosis or treatment decisions, is regulated by the Saudi Food and Drug Authority under its medical devices framework, which requires establishment licensing, product classification, and registration on the national medical device database before marketing, along with conformity to recognized international standards for software as a medical device. Analytics products handling personal health information are also subject to the Personal Data Protection Law, overseen by the Saudi Data and Artificial Intelligence Authority, which sets requirements for lawful processing, consent, and safeguarding of sensitive data. Suppliers should expect both device-level and data-governance obligations to apply.

Competition in Saudi Arabia runs between the suppliers this study tracks: McKesson Corporation, Optum, Inc., IBM, Oracle, SAS Institute, Inc., IQVIA, Verisk Analytics, Inc., Elsevier, Medeanalytics, Inc., Truven Health Analytics, Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Health Catalyst and Innovaccer Inc.. The commercially relevant division is 40% of 2025 revenue in Descriptive Analysis, where the volume is, against 22.95% growth in Prescriptive Analysis, where share moves.

Within Middle East and Africa, the United Arab Emirates accounts for 22.07% of regional revenue and 1.1% of the global total, worth USD 0.64 billion in 2025 and USD 2.86 billion by 2034.

0.9% of global revenue is generated in South Africa; USD 0.52 billion in 2025, reaching USD 2.34 billion in 2034, and 17.93% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, component, delivery mode, application, end-use, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.